Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Publications

Supp Table 4 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 4 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 5 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 5 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 6 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 6 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 7 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 7 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supplementary Information from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supplementary Information from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Correction: Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients.

Ryou H. et al, (2023), Leukemia

CHROMOTHRIPSIS AND LEUKEMIC TRANSFORMATION IN MPN

Brierley C. et al, (2023), EXPERIMENTAL HEMATOLOGY, 124, S65 - S65

Modelling the pathology and treatment of cardiac fibrosis in vascularised atrial and ventricular cardiac microtissues

Reyat JS. et al, (2023), Frontiers in Cardiovascular Medicine, 10

Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients

HARRINGTON H. et al, (2022), Leukemia

Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients.

Ryou H. et al, (2022), Leukemia

CNL and aCML should be considered as single entity based on molecular profiles and outcomes.

Carreño-Tarragona G. et al, (2022), Blood Adv

Human bone marrow organoids for disease modelling, discovery and validation of therapeutic targets in hematological malignancies.

Khan AO. et al, (2022), Cancer Discov

Single-cell methods in myeloproliferative neoplasms - old questions, new technologies.

O'Sullivan JM. et al, (2022), Blood

CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies.

Bueno C. et al, (2022), Blood, 140, 38 - 44

A tale of two alleles: TP53 and transformation in MPNs.

Brierley C. and Psaila B., (2022), Blood, 139, 3567 - 3568